738-P: Real-World Effectiveness among Patients with Type 2 Diabetes (T2D) Initiating Tirzepatide (TZP)

Introduction 7% vs ≥7%) were described. Results: Among 2,247 identified pts: mean age 54 years, 58% female, 46% no prior GLP-1 RA use, 59% A1C ≥7%, 61% had overweight/obesity. At 6-month follow up, mean pre-post change in A1C was -1.0% in the overall cohort, -1.4% among pts with baseline A1C ≥7%, and -1.3% in those without prior GLP-1 RA use. Mean change in weight was -6.3 kgs for overall cohort, -5.8 kgs in pts with baseline A1C ≥7%, and -8.1 kgs in those without prior GLP-1 RA use. Further outcomes are summarized in Table 1. Conclusion: At 6-month follow up, pts initiating TZP in the real world showed reductions in A1C and weight, with greater A1C decreases observed among pts with no prior GLP-1 RA use or with baseline A1C ≥7%. Disclosure R. Mody: Employee; Eli Lilly and Company. K. Desai: Employee; Carelon Research. Stock/Shareholder; Anthem, Inc. C. Teng: Employee; Carelon Research. G. Reznor: None. G. Stockbower: None. M. Grabner: Employee; Carelon Research. Stock/Shareholder; Anthem, Inc. B.D. Benneyworth: Employee; Eli Lilly and Company. Stock/Shareholder; Eli Lilly and Company.